Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public the negotiated prices they pay for drugs.
Advocates say a new rule will make it harder for patients with conditions such as cancer and multiple sclerosis who rely on very expensive drugs to afford them.
The drug company trade group PhRMA has filed a legal challenge to a pair of Oregon laws designed to curb prescription prices.
The Pharmaceutical Research and Manufacturers of America filed suit in Eugene against two bills that passed the Oregon Legislature with bipartisan support.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
SALEM – For six years, Oregon pharmacies have been lobbying the state Legislature to rein in fees imposed on them by pharmacy benefit managers, the third-party intermediaries that negotiate prices with drug manufacturers and prescription drug claims with insurers.
Medicare enrollees, who have watched their out-of-pocket spending on prescription drugs climb in recent years, might be in for a break.
Access to powerful new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of people whose doctors prescribe the drugs get them, a new study found.
Who contributes to what you pay at the pharmacy? Why are prescription drugs so expensive in the United States?
Even before media reports and a congressional hearing vilified Valeant Pharmaceuticals International for raising prices on a pair of lifesaving heart drugs, Dr. Umesh Khot knew something was very wrong. Khot is a cardiologist at the Cleveland Clinic, which prides itself on outstanding heart care. The health system’s pharmacists had alerted doctors about the skyrocketing cost of the drugs, nitroprusside and isoproterenol. But these two older drugs, frequently used in emergency and intensive care situations, have no direct alternatives.
The pharmaceutical industry could see windfall profits from a little-noticed tweak to the insurance market tucked into the Trump administration’s draft executive order on drug prices, experts say.